Literature DB >> 26775651

Ovarian Stimulation Protocol in IVF: An Up-to-Date Review of the Literature.

Alessandro Pacchiarotti, Helmy Selman1, Claudia Valeri, Simona Napoletano, Marco Sbracia, Gabriele Antonini, Giulio Biagiotti, Arianna Pacchiarotti.   

Abstract

The Assisted Reproductive Technology (ART) was born in order to help couples with infertility issues in having a baby. The first treatments of IVF used the spontaneous cycle of the women, with the retrieval of only one oocyte. Further studies have shown that it is possible to induce ovulation by administrating gonadotropins during the menstrual cycle, in order to obtain a higher number of oocytes. Many stimulation protocols have been introduced for controlled ovarian hyperstimulation of patients undergoing in vitro fertilization treatment. This review describe the different stimulation protocols using follicle-stimulating hormone (FSH) in combination with Gonadotropin releasing hormone (GnRH) either agonist or antagonist, oral supplementations and ovarian triggering. Using GnRH antagonist protocols have been demonstrated to improve significantly the clinical pregnancy rates for expected poor and high-responders, and in those women at high risk of developing ovarian hyperstimulation syndrome (OHSS). Two meta-analyses showed a better outcome in terms of the live birth rate when highly purified human menopausal gonadotropin (HMG) was used for ovarian stimulation compared with recombinant follicle stimulating hormone (rFSH) in the GnRH agonist long protocol. One of the most efficient stimulation protocol is the use of a combined protocol of human derived urinary FSH (uFSH) and rFSH. Combined protocol has resulted in a significant increase in the proportion of mature metaphase II oocytes and grade 1 embryos when compared to either rFSH or uFSH alone. A significantly higher delivery rate was achieved in rFSH+uFSH compared to the other protocols in poor and normal responders. Studying the combination of melatonin with myo-inositol and folic acid has also showed a higher percentage of mature oocytes in the melatonin group and a higher percentage of G1 embryos as well. However, It remains a crucial step to confirm the efficacy of such protocols for clinical application and it is still needs to comparison studies on larger scale with more focused on the differences in patients' response criteria and additional confounding variables, in order to draw more defined conclusions.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26775651     DOI: 10.2174/1389201017666160118103147

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  13 in total

Review 1.  Fshb Knockout Mouse Model, Two Decades Later and Into the Future.

Authors:  T Rajendra Kumar
Journal:  Endocrinology       Date:  2018-05-01       Impact factor: 4.736

2.  Preconception serum lipids and lipophilic micronutrient levels are associated with live birth rates after IVF.

Authors:  Erica L Jamro; Michael S Bloom; Richard W Browne; Keewan Kim; Eleni A Greenwood; Victor Y Fujimoto
Journal:  Reprod Biomed Online       Date:  2019-06-14       Impact factor: 3.828

3.  Dietary folate intake and modification of the association of urinary bisphenol A concentrations with in vitro fertilization outcomes among women from a fertility clinic.

Authors:  Lidia Mínguez-Alarcón; Audrey J Gaskins; Yu-Han Chiu; Irene Souter; Paige L Williams; Antonia M Calafat; Russ Hauser; Jorge E Chavarro
Journal:  Reprod Toxicol       Date:  2016-07-14       Impact factor: 3.143

4.  What is the true place of a double stimulation and double oocyte retrieval in the same cycle for patients diagnosed with poor ovarian reserve? A systematic review including a meta-analytical approach.

Authors:  Konstantinos Sfakianoudis; Konstantinos Pantos; Sokratis Grigoriadis; Anna Rapani; Evangelos Maziotis; Petroula Tsioulou; Polina Giannelou; Adamantia Kontogeorgi; Agni Pantou; Nikolaos Vlahos; Michael Koutsilieris; Mara Simopoulou
Journal:  J Assist Reprod Genet       Date:  2019-12-03       Impact factor: 3.412

5.  The effect of lysophosphatidic acid-supplemented culture medium on human immature oocytes matured in vitro.

Authors:  Qigui Xie; Yaxin Xing; Jianhong Zhou; Ling Wang; Jie Wu; Ri-Cheng Chian
Journal:  Reprod Biol Endocrinol       Date:  2021-06-04       Impact factor: 5.211

6.  Differences in utilization of Intracytoplasmic sperm injection (ICSI) within human services (HHS) regions and metropolitan megaregions in the U.S.

Authors:  Pavel Zagadailov; Albert Hsu; David B Seifer; Judy E Stern
Journal:  Reprod Biol Endocrinol       Date:  2017-06-12       Impact factor: 5.211

7.  Cumulative Live Birth Rates After the First ART Cycle Using Flexible GnRH Antagonist Protocol vs. Standard Long GnRH Agonist Protocol: A Retrospective Cohort Study in Women of Different Ages and Various Ovarian Reserve.

Authors:  Wanlin Zhang; Duo Xie; Hengde Zhang; Jianlei Huang; Xifeng Xiao; Binrong Wang; Yafei Tong; Ye Miao; Xiaohong Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-08       Impact factor: 5.555

8.  Frozen thawed embryo transfer cycles; A comparison of pregnancy outcomes with and without prior pituitary suppression by GnRH agonists: An RCT.

Authors:  Alamtaj Samsami; Zohre Chitsazi; Golnaz Namazi
Journal:  Int J Reprod Biomed       Date:  2018-09

9.  Evaluation of the safety and efficacy of corifollitropin alfa combined with GnRH agonist triggering in oocyte donation cycles. A prospective longitudinal study.

Authors:  Ioannis Tsakiridis; Robert Najdecki; Petroula Tatsi; Evi Timotheou; Kallirhoe Kalinderi; Georgios Michos; Andriana Virgiliou; Hakan Yarali; Apostolos Athanasiadis; Evangelos G Papanikolaou
Journal:  JBRA Assist Reprod       Date:  2020-10-06

10.  Initial ovarian sensitivity index predicts embryo quality and pregnancy potential in the first days of controlled ovarian stimulation.

Authors:  David Camargo-Mattos; Uziel García; Felipe Camargo-Diaz; Ginna Ortiz; Ivan Madrazo; Esther Lopez-Bayghen
Journal:  J Ovarian Res       Date:  2020-08-17       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.